ARR-217 (MRG007) — Interim data
H2 2026
Plan to complete Phase 1 dose escalation and enter into dose optimization for ARR-217, a CDH17 targeting ADC program, in the second half of 2026.Source filing
AVBP biotech catalysts & pipeline
ARRIVENT BIOPHARMA INC · Data as of 2026-10-25